📊 SVRA Key Takeaways
Is Savara Inc (SVRA) a Good Investment?
Savara is a pre-revenue or severely distressed pharmaceutical company with zero reported revenue, massive operating losses of -$39M, and negative free cash flow of -$33.1M annually. With only $38.8M in cash reserves against a burn rate of ~$33M per year, the company faces critical liquidity concerns with approximately 14 months of runway remaining.
Savara Inc Key Strengths (SVRA)
- Strong liquidity position with 13.47x current ratio and quick ratio indicating ability to meet short-term obligations
- Conservative capital structure with 0.17x debt/equity ratio and only $30.1M long-term debt limiting financial distress risk
- Stockholders' equity of $176M provides asset backing, though severely impaired by operational losses
SVRA Stock Risks: Savara Inc Investment Risks
- Zero revenue indicates no commercial viability or complete product failure requiring urgent pipeline advancement
- Negative operating cash flow of -$33M annually with limited runway of approximately 14 months at current burn rate
- Unable to cover interest expenses from operations (interest coverage ratio of -179.7x) indicating dependency on equity or asset sales
- Sector-specific risk: pharmaceutical development dependency on successful FDA approvals and market adoption with uncertain timelines
- Dilution risk evident in worsening EPS (-0.15, -10.4% YoY) suggesting multiple capital raises
Key Metrics to Watch
- Monthly cash burn rate and remaining runway to avoid insolvency
- Revenue generation milestones and product pipeline approval status
- Operating cash flow inflection points indicating path to profitability
- Debt covenant compliance and refinancing requirements
Savara Inc (SVRA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 13.47x current ratio provides a solid financial cushion.
SVRA Profit Margin, ROE & Profitability Analysis
SVRA vs Healthcare Sector: How Savara Inc Compares
How Savara Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Savara Inc Stock Overvalued? SVRA Valuation Analysis 2026
Based on fundamental analysis, Savara Inc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Savara Inc Balance Sheet: SVRA Debt, Cash & Liquidity
SVRA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Savara Inc's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.48 indicates the company is currently unprofitable.
SVRA Revenue Growth, EPS Growth & YoY Performance
SVRA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2021 | N/A | -$9.4M | N/A |
| Q3 2020 | $256.0K | -$9.4M | N/A |
| Q2 2020 | N/A | -$9.1M | N/A |
| Q1 2020 | N/A | -$12.1M | N/A |
| Q3 2019 | N/A | -$11.6M | N/A |
| Q2 2019 | N/A | -$11.6M | N/A |
| Q1 2019 | N/A | -$12.1M | N/A |
| Q1 2018 | N/A | -$4.8M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Savara Inc Dividends, Buybacks & Capital Allocation
SVRA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Savara Inc (CIK: 0001160308)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SVRA
What is the AI rating for SVRA?
Savara Inc (SVRA) has an AI grade of D with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SVRA's key strengths?
Claude: Strong liquidity position with 13.47x current ratio and quick ratio indicating ability to meet short-term obligations. Conservative capital structure with 0.17x debt/equity ratio and only $30.1M long-term debt limiting financial distress risk.
What are the risks of investing in SVRA?
Claude: Zero revenue indicates no commercial viability or complete product failure requiring urgent pipeline advancement. Negative operating cash flow of -$33M annually with limited runway of approximately 14 months at current burn rate.
What is SVRA's revenue and growth?
Savara Inc reported revenue of $0.0.
Does SVRA pay dividends?
Savara Inc pays dividends, with $0.2M distributed to shareholders in the trailing twelve months.
Where can I find SVRA SEC filings?
Official SEC filings for Savara Inc (CIK: 0001160308) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SVRA's EPS?
Savara Inc has a diluted EPS of $-0.15.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SVRA's fundamental grade?
Based on our AI fundamental analysis in June 2026, Savara Inc has a D grade with 92% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SVRA stock overvalued or undervalued?
Valuation metrics for SVRA: ROE of -21.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SVRA's AI grade for 2026?
Our dual AI analysis gives Savara Inc a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SVRA's free cash flow?
Savara Inc's operating cash flow is $-33.0M, with capital expenditures of $54.0K.
How does SVRA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -21.2% (avg: 15%), current ratio 13.47 (avg: 2).